synthetic conjugate polysaccharide vaccine haemophilus influenzae type b 
glycoconjugate vaccines provide effective prophylaxis bacterial infections date however commercial vaccine available key carbohydrate antigens produced synthetically describe large-scale synthesis pharmaceutical development clinical evaluation conjugate vaccine composed synthetic capsular polysaccharide antigen haemophilus influenzae type b hib vaccine evaluated clinical trials cuba showed long-term protective antibody titers compared favorably licensed products prepared hib polysaccharide extracted bacteria demonstrates access synthetic complex carbohydrate based vaccines feasible provides basis development similar approaches human pathogens 
